RYTM did a 120% run in November and December and then pivoted to start the year. It competes
in the anti-obesity drug space which is all the rage right now and has snack food manufactures
freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382
retracement level and then pivoting into a reversal in the past week. The dual...